How many billions is enough? Prioritizing profits over patients with cystic fibrosis.
作者信息
McGarry Meghan E, Gibb Elizabeth R, Laguna Theresa A, O'Sullivan Brian P, Sawicki Gregory S, Zobell Jeffery T
机构信息
Department of Pediatrics, Division of Pediatric Pulmonary Medicine, University of California San Francisco, San Francisco, California, USA.
Department of Pediatrics, Division of Pulmonary Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
出版信息
Pediatr Pulmonol. 2023 May;58(5):1595-1597. doi: 10.1002/ppul.26335. Epub 2023 Feb 10.
Abstract
摘要
相似文献
1
How many billions is enough? Prioritizing profits over patients with cystic fibrosis.
Pediatr Pulmonol. 2023 May;58(5):1595-1597. doi: 10.1002/ppul.26335. Epub 2023 Feb 10.
2
A personalized medicine approach to optimize care for a pediatric cystic fibrosis patient with atypical clinical symptoms.
Pediatr Pulmonol. 2024 Jan;59(1):229-232. doi: 10.1002/ppul.26719. Epub 2023 Oct 11.
3
[Challenges of personalized medicine for cystic fibrosis].
Arch Pediatr. 2015 Jul;22(7):778-86. doi: 10.1016/j.arcped.2015.04.015. Epub 2015 May 26.
4
Towards personalized medicine for cystic fibrosis patients with rare mutations.
J Physiol. 2024 Jan;602(2):257-258. doi: 10.1113/JP286135. Epub 2024 Jan 3.
5
Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator.
Am J Respir Crit Care Med. 2014 Mar 15;189(6):746-8. doi: 10.1164/rccm.201312-2144LE.
6
Nasal epithelial cells as a gold-standard predictive model for personalized medicine in cystic fibrosis.
J Physiol. 2022 Mar;600(6):1285-1286. doi: 10.1113/JP282586. Epub 2022 Jan 31.
7
A new era of personalized medicine for cystic fibrosis - at last!
Can Respir J. 2015 Sep-Oct;22(5):257-60. doi: 10.1155/2015/921712. Epub 2015 Jun 17.
8
Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis.
Clin Chest Med. 2022 Dec;43(4):617-630. doi: 10.1016/j.ccm.2022.06.005.
9
Personalised medicine for cystic fibrosis: treating the basic defect.
Eur Respir Rev. 2013 Mar 1;22(127):3-5. doi: 10.1183/09059180.00008112.
10
Personalized medicine for cystic fibrosis: establishing human model systems.
Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S14-23. doi: 10.1002/ppul.23233.
引用本文的文献
1
Building Lay Society Knowledge and Education for Health Technology Assessment and Policy Engagement: Case of CFTR Modulator Access in Brazil.
Healthcare (Basel). 2025 Aug 14;13(16):1996. doi: 10.3390/healthcare13161996.
2
The ethics and economics of organoid commercialization: potential donors' perspectives.
BMC Med Ethics. 2025 Jul 29;26(1):109. doi: 10.1186/s12910-025-01269-3.
3
Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter!
Am J Respir Crit Care Med. 2023 Nov 1;208(9):915-916. doi: 10.1164/rccm.202307-1200VP.
4
Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns.
Sci Rep. 2023 Jun 1;13(1):8910. doi: 10.1038/s41598-023-35942-7.
5
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.
J Cyst Fibros. 2023 Jul;22(4):652-655. doi: 10.1016/j.jcf.2023.04.007. Epub 2023 Apr 24.
6
Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!
Front Pharmacol. 2023 Mar 27;14:1163391. doi: 10.3389/fphar.2023.1163391. eCollection 2023.
7
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.
本文引用的文献
1
Current prices versus minimum costs of production for CFTR modulators.
J Cyst Fibros. 2022 Sep;21(5):866-872. doi: 10.1016/j.jcf.2022.04.007. Epub 2022 Apr 16.
2
Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.
Paediatr Respir Rev. 2022 Jun;42:35-42. doi: 10.1016/j.prrv.2021.12.001. Epub 2021 Dec 22.
3
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC.
4
The effectiveness and value of novel treatments for cystic fibrosis.
J Manag Care Spec Pharm. 2021 Feb;27(2):276-280. doi: 10.18553/jmcp.2021.27.2.276.
5
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
6
Pregnancy among cystic fibrosis women in the era of CFTR modulators.
J Cyst Fibros. 2017 Nov;16(6):687-694. doi: 10.1016/j.jcf.2017.01.008. Epub 2017 Feb 10.
Zotero 插件